Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab Therapeutics (Nasdaq: CMMB) announced the appointment of Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. These appointments aim to strengthen the development of CM-101, a monoclonal antibody targeting fibrotic and inflammatory diseases. Key upcoming events include reporting topline results from a Phase 2 trial in liver fibrosis and launching a Phase 2 trial for systemic sclerosis. Both executives bring significant expertise that is expected to accelerate Chemomab's clinical activities and pipeline programs.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced it will release its second quarter 2022 financial results and provide a business update on August 12, 2022, at 8:00 am Eastern Time. During this event, the management team will review Q2 performance, discuss recent developments, and host a live Q&A session. The company specializes in developing therapeutics for fibrotic and inflammatory diseases, focusing on its monoclonal antibody CM-101, which is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported significant findings from presentations at the 2022 EASL International Liver Congress and the First International Extracellular Matrix Pharmacology Congress. The data highlights the role of the soluble protein CCL24 in liver diseases, specifically primary sclerosing cholangitis (PSC). Findings suggest that Chemomab's CCL24 neutralizing antibody CM-101 can effectively influence extracellular matrix remodeling, showing promise in clinical applications for PSC. The studies support the ongoing development of CM-101 in Phase 2 trials.
Chemomab Therapeutics (Nasdaq: CMMB) has appointed Jill M. Quigley to its board of directors. Quigley brings over 20 years of experience in biotechnology leadership, including executive roles in management, operations, and legal affairs. Her expertise includes working with companies focused on innovative therapeutics for rare diseases. Chemomab is advancing its antibody CM-101 through clinical trials for serious conditions like primary sclerosing cholangitis and systemic sclerosis. This appointment is expected to enhance Chemomab's strategic direction and operational efficacy.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its participation in various investor and scientific conferences in June 2022, aimed at presenting its groundbreaking work in fibrotic and inflammatory diseases. Notable events include the JMP Securities Life Sciences Conference on June 16 in New York, and the Extracellular Matrix Pharmacology Congress from June 23-25 in Copenhagen. Chemomab's lead asset, CM-101, is in Phase 2 trials for several severe conditions, including primary sclerosing cholangitis, and is expected to advance into systemic sclerosis trials later this year.
Chemomab Therapeutics reported significant findings regarding CCL24 as a therapeutic target for systemic sclerosis at the EULAR European Congress of Rheumatology. Their CCL24-neutralizing antibody, CM-101, is set to enter Phase 2 trials later this year. The study indicated elevated CCL24 levels correlated with disease activity and prognosis in diffuse cutaneous systemic sclerosis patients. These findings strengthen the rationale for CM-101's clinical trials, aimed at addressing a critical unmet need in treating this severe autoimmune disease.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual H.C. Wainwright Global Investment Conference from May 23-26, 2022. Management will deliver a corporate overview webcast available on demand starting at 7:00 am ET on May 24. Additionally, Chemomab will engage in one-on-one meetings with investors. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in Phase 2 trials for severe conditions like primary sclerosing cholangitis and lung fibrosis.
Chemomab Therapeutics (CMMB) reported its Q1 2022 financial results, revealing a net loss of $5.1 million, or $0.02 per share, compared to a $1.7 million loss in Q1 2021. Cash and equivalents decreased to $57.5 million from $61.2 million at year-end 2021. R&D expenses rose significantly to $2.7 million, while G&A expenses jumped to $2.6 million, influenced by stock-based compensation. The company is progressing in its CM-101 clinical trial for fibrotic diseases, expanding into new regions, with an interim analysis expected later this year.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its first quarter 2022 financial results and provide a business update on May 12, 2022, during a conference call at 8:00 am ET. The call will review performance, recent events, and feature a live Q&A session. Chemomab focuses on developing therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in two Phase 2 trials for severe conditions affecting the liver and systemic sclerosis. For further details, visit chemomab.com.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022. Co-founder and Chief Scientific Officer Adi Mor will be a panelist. The discussion will focus on 'Platforms and Pipelines in a Product', highlighting potential applications across various rare diseases. Chemomab specializes in innovative therapies for fibrotic and inflammatory diseases, with their lead product, CM-101, in Phase 2 trials for multiple conditions.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
